212 related articles for article (PubMed ID: 11395570)
41. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
42. Transepithelial transport mechanisms of 7,8-dihydroxyflavone, a small molecular TrkB receptor agonist, in human intestinal Caco-2 cells.
Chen Y; Xue F; Xia G; Zhao Z; Chen C; Li Y; Zhang Y
Food Funct; 2019 Aug; 10(8):5215-5227. PubMed ID: 31384856
[TBL] [Abstract][Full Text] [Related]
43. Investigation of the Uptake and Transport of Two Novel Camptothecin Derivatives in Caco-2 Cell Monolayers.
Wang Y; Zhang X; Zhuang W; Yu Y; Sun X; Wang H; Li F; Li Q
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744795
[TBL] [Abstract][Full Text] [Related]
44. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen RH; van Alphen RJ; Verweij J; Loos WJ; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2001 Aug; 7(8):2182-94. PubMed ID: 11489791
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
[TBL] [Abstract][Full Text] [Related]
46. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
Park DJ; Won JH; Cho AR; Yun HJ; Heo JH; Hwhang TH; Lee DH; Kim WM
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():147-152. PubMed ID: 24927278
[TBL] [Abstract][Full Text] [Related]
47. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Guo S; Zhang X; Gan L; Zhu C; Gan Y
J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
[TBL] [Abstract][Full Text] [Related]
48. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
49. Pharmacogenetics of irinotecan metabolism and transport: an update.
Smith NF; Figg WD; Sparreboom A
Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446
[TBL] [Abstract][Full Text] [Related]
50. Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: A new concept.
Martha L; Nakata A; Furuya S; Liu W; Zhang X; Mizoi K; Ogihara T
Biochem Biophys Res Commun; 2023 Jul; 665():19-25. PubMed ID: 37148742
[TBL] [Abstract][Full Text] [Related]
51. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.
Chu XY; Kato Y; Sugiyama Y
Drug Metab Dispos; 1999 Apr; 27(4):440-1. PubMed ID: 10101137
[TBL] [Abstract][Full Text] [Related]
52. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
53. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
54. [Pharmacokinetic study of cancer chemotherapy].
Itoh T
Yakugaku Zasshi; 2006 Sep; 126(9):723-35. PubMed ID: 16946586
[TBL] [Abstract][Full Text] [Related]
55. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
56. Mechanism of intestinal transport of an organic cation, tributylmethylammonium in Caco-2 cell monolayers.
Hong SS; Moon SC; Shim CK
Arch Pharm Res; 2006 Apr; 29(4):318-22. PubMed ID: 16681038
[TBL] [Abstract][Full Text] [Related]
57. Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2.
Vaidyanathan JB; Walle T
Pharm Res; 2001 Oct; 18(10):1420-5. PubMed ID: 11697467
[TBL] [Abstract][Full Text] [Related]
58. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
[TBL] [Abstract][Full Text] [Related]
60. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H
Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]